Trimetazidine

Trimetazidine

SCHEMBL230374

COc1ccc(CN2CCNCC2)c(OC)c1OC

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 2/20 1.00
OPRK1 P41145 2/20 1.00
CYP1A2 P05177 1/20 1.00
SLC6A4 P31645 1/20 1.00
OPRD1 P41143 1/20 1.00
APOBEC3A P31941 1/20 0.97
CTDSP1 Q9GZU7 1/20 0.97
APOBEC3G Q9HC16 1/20 0.97
KDM4E B2RXH2 2/20 0.60
LMNA P02545 2/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
MEN1 O00255 6/20 0.55
KMT2A Q03164 6/20 0.55
HTT P42858 2/20 0.55
CYP2C19 P33261 1/20 0.55
ADORA3 P0DMS8 1/20 0.55
CHRM1 P11229 1/20 0.55
DRD2 P14416 1/20 0.55
ADRA2B P18089 1/20 0.55
ADRA2C P18825 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trimetazidine SCHEMBL11846840 1.00 CHRM2 (1.00) CHRM2OPRK1CYP1A2SLC6A4OPRD1
Trimetazidine SCHEMBL29375563 1.00 CHRM2 (1.00) CHRM2OPRK1CYP1A2SLC6A4OPRD1
Trimetazidine SCHEMBL3896420 0.98 CHRM2 (0.97) CHRM2OPRK1CYP1A2SLC6A4OPRD1
Trimetazidine SCHEMBL29605009 0.98 APOBEC3A (1.00) CHRM2OPRK1CYP1A2SLC6A4OPRD1
Trimetazidine SCHEMBL580378 0.98 APOBEC3A (1.00) CHRM2OPRK1CYP1A2SLC6A4OPRD1
Trimetazidine SCHEMBL15302482 0.98 CHRM2 (0.97) CHRM2OPRK1CYP1A2SLC6A4OPRD1
Trimetazidine SCHEMBL2901538 0.98 APOBEC3A (1.00) CHRM2OPRK1CYP1A2SLC6A4OPRD1
Trimetazidine SCHEMBL348591 0.98 APOBEC3A (1.00) CHRM2OPRK1CYP1A2SLC6A4OPRD1
Trimetazidine SCHEMBL29677959 0.98 APOBEC3A (1.00) CHRM2OPRK1CYP1A2SLC6A4OPRD1
Trimetazidine SCHEMBL12485382 0.97 CHRM2 (0.94) CHRM2OPRK1CYP1A2SLC6A4OPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 4212 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122075493-A Compound pharmaceutical preparation for treating chronic uricosuric nephropathy and application thereof 2026-05-26 CN claimed
US-12616691-B2 Use of fatty acid oxidation inhibitors as antimicrobials WASHINGTON UNIVERSITY IN ST. LOUIS (US) 2026-05-05 US claimed
US-20260115145-A1 Method for Enhancing Drug Solubility and Preparing a Drug Composite Material with Enhanced Solubility PHARMAEASE TECH LTD (CN) 2026-04-30 US claimed
EP-4731194-A1 MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT CSP Technologies, Inc. (US) 2026-04-29 EP claimed
US-12599614-B2 Methods and pharmaceutical compositions for the treatment and prophylaxis of microbial infectious diseases and associated inflammatory disorders and for the treatment and prophylaxis of aging and associated diseases MD VAULT LLC (US) 2026-04-14 US claimed
EP-4722714-A1 SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) Korea Institute of Science and Technology (KR) 2026-04-08 EP claimed
EP-4687805-A1 MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING ACTIVATED CARBON OR A DERIVATIVE THEREOF CSP Technologies, Inc. (US) 2026-02-11 EP claimed
US-20260027008-A1 MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING ACTIVATED CARBON OR A DERIVATIVE THEREOF CSP TECHNOLOGIES, INC. 2026-01-29 US claimed
EP-4023225-B1 COMBINATIONS OF A SALICYLATE AND TRIMETAZIDINE FOR USE IN THE TREATMENT OF METABOLIC DISEASES INST ZOOLOGY CAS (CN) 2026-01-28 EP claimed
WO-2025264260-A1 MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT CSP TECHNOLOGIES, INC. (US) 2025-12-26 WO claimed
EP-0673649-A1 Pharmaceutical compositions for the prolonged release of trimetazidine after oral administration ADIR ET COMPAGNIE (FR) 1995-09-27 EP claimed
EP-0453365-B1 Process for the preparation of 1-(2,3,4-trimethoxybenzyl) piperazine by reductive amination ADIR (FR) 1994-11-30 EP claimed
EP-0613686-A1 Use of trimetazidine for the preparation of medicaments for the treatment of troubles due to the therapeutical use of immunosuppressants ADIR ET COMPAGNIE (FR) 1994-09-07 EP claimed
EP-0585155-A1 Trifluoromethylketone derivatives of peptides having HLE inhibiting activity, their preparation and pharmaceutical composition ADIR ET COMPAGNIE (FR) 1994-03-02 EP claimed
US-5283246-A Trimetazidine compounds ADIR ET COMPAGNIE (FR) 1994-02-01 US claimed
EP-0533579-A1 Trimetazidine derivatives, process for their preparation and pharmaceutical compositions containing them ADIR ET COMPAGNIE (FR) 1993-03-24 EP claimed
US-5142053-A PROCESS FOR THE PREPARATION OF 1-(2,3,4-TRIMETHOXYBENZYL)PIPERAZINE BY REDUCTIVE ANIMATION ADIR ET COMPAGNIE (FR) 1992-08-25 US claimed
EP-0453365-A1 Process for the preparation of 1-(2,3,4-trimethoxybenzyl) piperazine by reductive amination ADIR ET COMPAGNIE (FR) 1991-10-23 EP claimed
US-4407801-A HIGH DOSAGE OF 1-(2,3,4-TRIMETHOXYBENZYL)PIPERAZINE AND A DISINTEGRATING AGENT SCIENCE UNION ET CIE (FR) 1983-10-04 US claimed
US-3959281-A CORONARY DILATORS CASSELLA FARBWERKE MAINKUR AKTIENGESELLSCHAFT (DT) 1976-05-25 US claimed